2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Gene Editing, Treatment Considerations, Supportive Care, Biological Therapies, Transfusion, Gene Therapy, Workforce, Adverse Events, Artificial Intelligence (AI), Natural Language Processing, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Value, Diseases, Genetic Disorders, Hemoglobinopathies, Sickle Cell Disease, Thalassemia, Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Pediatric
PAPER

2604 Gaps in longitudinal ophthalmology screening among adults with sickle cell disease: Missed opportunities for early detection of sickle cell retinopathy

Mana Yacim, M.Ed, Jennifer Marie Jones, MD2
1 University of Michigan, Ann Arbor, Michigan, United States
2 University of Michigan, Ann Arbor, Michigan, United States, University of Michigan, Ann Arbor, Michigan, United States
Introduction:

Sickle cell retinopathy (SCR) is a progressive complication of sickle cell disease (SCD) that can cause severe visual impairment and blindness due to vitreous hemorrhage and retinal detachment (Cummings OW et al., 2024). Despite national guideline recommendations for dilated retinal examination every one to two years, real-world adherence to longitudinal ophthalmologic screening remains poorly characterized. In this single center study, we sought to describe longitudinal adherence to SCR screening guidelines and correlate screening frequency with timing of SCR diagnosis.  

Methods:

A retrospective cohort study was performed to evaluate SCR screening practices at a single institution.  Adults (> 18 years of age) with confirmed SCD identified by electronic medical record (EMR) review were eligible for inclusion. Variables collected from the EMR included demographic characteristics, ophthalmology referrals, completed ophthalmology encounters, retinal subspecialty visits, and SCR diagnosis dates. 

The primary outcome was longitudinal adherence to SCR screening, defined as completion of at least one ophthalmology visit every two years. Only subjects with at least two years of follow-up were considered for this analysis. 

Descriptive statistics were performed. Categorical and continuous data were summarized with counts (percentages) and medians with interquartile ranges, respectively. Univariate and multivariate logistic regression was performed to associate covariates with the diagnosis of SCR. Statistical analysis was completed in Stata/BE Version 18.5 and Microsoft Excel.

Results:

Of 136 identified subjects with SCD, 129 (95%) subjects had at least two years of follow-up, and only 12 (9.3%) met longitudinal screening recommendations. In total, 117 (86%) subjects were referred to or otherwise established with ophthalmology, and 95 (70%) had at least one ophthalmology visit. Hematologists initiated 76% of referrals compared with 16% by primary care. Among patients completing at least one ophthalmology visit, 42% were subsequently lost to follow-up in ophthalmology for more than two years.

Twenty-eight subjects (26%) received a diagnosis of SCR. Of these, nine subjects (32%), including four with more advanced disease (proliferative retinopathy, PSR) received the diagnosis at their first ophthalmology visit. An additional four subjects were diagnosed with PSR within six months of establishing care in ophthalmology. Seventy-three percent of subjects were diagnosed with SCR within one year and 84% within two years of the initial ophthalmology visit. The HbSC genotype was more prevalent among patients with SCR compared to those without SCR (46% vs. 21%, p=0.010). HbSC genotype remained independently associated with SCR (OR 2.69, 95% confidence interval 1.03–7.01, p=0.043), after controlling for age and sex.

Conclusion:

In this single center study of SCR screening, ophthalmology referrals were common but longitudinal adherence to guideline-recommended screening was poor. Several patients were diagnosed with later-stage SCR at the first ophthalmology screening visit or within one year, which may suggest global delays in establishing care with ophthalmology. As the primary service to recognize the importance of SCR screening and place ophthalmology referrals, hematology is well-positioned to advocate for more robust eye care infrastructure for patients with SCD, especially those with HbSC disease. Identification of opportunities to partner with ophthalmology and develop collective solutions to improve screening cadence will facilitate earlier identification of SCR and reduce vision-threatening complications of SCD. 

Mana Yacim, M.Ed: No relevant conflicts of interest to declare.